177 related articles for article (PubMed ID: 14612552)
1. Calgranulins in cystic fluid and serum from patients with ovarian carcinomas.
Ott HW; Lindner H; Sarg B; Mueller-Holzner E; Abendstein B; Bergant A; Fessler S; Schwaerzler P; Zeimet A; Marth C; Illmensee K
Cancer Res; 2003 Nov; 63(21):7507-14. PubMed ID: 14612552
[TBL] [Abstract][Full Text] [Related]
2. Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary.
Chudecka-Głaz A; Rzepka-Górska I; Kosmowska B
Arch Gynecol Obstet; 2004 Nov; 270(3):151-6. PubMed ID: 12883823
[TBL] [Abstract][Full Text] [Related]
3. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.
Wahlberg K; Høyer-Hansen G; Casslén B
Cancer Res; 1998 Aug; 58(15):3294-8. PubMed ID: 9699658
[TBL] [Abstract][Full Text] [Related]
4. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
[TBL] [Abstract][Full Text] [Related]
5. Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts.
Sundfeldt K; Ivarsson K; Rask K; Haeger M; Hedin L; Brännström M
Anticancer Res; 2001; 21(1A):65-70. PubMed ID: 11299791
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cyst fluids are a cache of tumor biomarkers that include calgranulin A and calgranulin B isoforms.
Skaggs HS; Saunders BA; Miller RW; Goodrich ST; King MS; Kimbler KD; Branscum AJ; Fung ET; DePriest PD; van Nagell JR; Ueland FR; Baron AT
Cancer Invest; 2013 Aug; 31(7):433-53. PubMed ID: 23915068
[TBL] [Abstract][Full Text] [Related]
7. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
Jones MB; Krutzsch H; Shu H; Zhao Y; Liotta LA; Kohn EC; Petricoin EF
Proteomics; 2002 Jan; 2(1):76-84. PubMed ID: 11788994
[TBL] [Abstract][Full Text] [Related]
8. Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors.
Arts HJ; de Jong S; Hollema H; Ten Hoor KA; de Vries EG; van der Zee AG
Int J Oncol; 2005 Feb; 26(2):379-84. PubMed ID: 15645122
[TBL] [Abstract][Full Text] [Related]
9. The chemotactic cytokine interleukin-8--a cyst fluid marker for malignant epithelial ovarian cancer?
Ivarsson K; Runesson E; Sundfeldt K; Haeger M; Hedin L; Janson PO; Brännström M
Gynecol Oncol; 1998 Dec; 71(3):420-3. PubMed ID: 9887242
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
11. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
Nowak M; Glowacka E; Szpakowski M; Szyllo K; Malinowski A; Kulig A; Tchorzewski H; Wilczynski J
Neuro Endocrinol Lett; 2010; 31(3):375-83. PubMed ID: 20588232
[TBL] [Abstract][Full Text] [Related]
12. Identification of S100A8 and S100A9 as serological markers for colorectal cancer.
Kim HJ; Kang HJ; Lee H; Lee ST; Yu MH; Kim H; Lee C
J Proteome Res; 2009 Mar; 8(3):1368-79. PubMed ID: 19186948
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
[TBL] [Abstract][Full Text] [Related]
14. [Placental protein 5 and pregnancy zone protein in ovarian cysts and benign cystic ovarian tumors].
Briese V; Than G; Richter D; Iino K; Seppälä M
Zentralbl Gynakol; 1988; 110(13):821-3. PubMed ID: 3176735
[TBL] [Abstract][Full Text] [Related]
15. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.
Jackson D; Craven RA; Hutson RC; Graze I; Lueth P; Tonge RP; Hartley JL; Nickson JA; Rayner SJ; Johnston C; Dieplinger B; Hubalek M; Wilkinson N; Perren TJ; Kehoe S; Hall GD; Daxenbichler G; Dieplinger H; Selby PJ; Banks RE
Clin Cancer Res; 2007 Dec; 13(24):7370-9. PubMed ID: 18094419
[TBL] [Abstract][Full Text] [Related]
16. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.
Ibanez de Caceres I; Battagli C; Esteller M; Herman JG; Dulaimi E; Edelson MI; Bergman C; Ehya H; Eisenberg BL; Cairns P
Cancer Res; 2004 Sep; 64(18):6476-81. PubMed ID: 15374957
[TBL] [Abstract][Full Text] [Related]
17. [Placental protein 12 (PP 12) in cyst and peritoneal fluids and serum samples of patients with ovarian cysts and cystic ovarian tumors].
Strache RR; Göcze PM; Szábo DG; Büttner HH; Briese V; Kunze M; Csaba IF; Röpcke G
Zentralbl Gynakol; 1989; 111(11):749-54. PubMed ID: 2781888
[TBL] [Abstract][Full Text] [Related]
18. Increased concentrations of neopterin in plasma, ascites and ovarian cyst fluid in malignant tumours compared with benign ovarian tumours.
Haeger M; Swahn M; Hahlin M; Horvath G; Bengtsson A
Anticancer Res; 1996; 16(5B):3189-92. PubMed ID: 8967734
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum thrombopoietin levels are higher in patients with ovarian cancer than with benign cysts.
Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
Eur J Obstet Gynecol Reprod Biol; 2008 Sep; 140(1):67-70. PubMed ID: 16359773
[TBL] [Abstract][Full Text] [Related]
20. Two-dimensional polyacrylamide gel electrophoresis map of bovine ovarian fluid proteins.
Mortarino M; Vigo D; Maffeo G; Ronchi S
Electrophoresis; 1999; 20(4-5):866-9. PubMed ID: 10344260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
